Description
The Tirzepatide 75mg Pen is a single disposable, prefilled pen containing 75 mg of tirzepatide in total.
Pricing
- 1 to 4 pens: $600 each
- 5 to 9 pens: $450 each
- 10 or more pens: $300 each
Ordering
A valid prescription is required. Every order is reviewed by our partner pharmacy before it is dispatched, and you will receive an email once it is approved. Payment is by cryptocurrency or cash on delivery.
Use only as directed by your prescribing doctor.
Clinical trial results: tirzepatide
Published phase 3 trials studied tirzepatide 5, 10 or 15 mg once weekly (marketed as Zepbound/Mounjaro) alongside lifestyle intervention. The strength sold on this page (75 mg pen) is not the presentation used in these trials.
| Trial | Population (n) | Dose / duration | Main result vs placebo | Source |
|---|---|---|---|---|
| SURMOUNT-1 (NEJM 2022) | Adults with obesity/overweight, no diabetes (n=2,539) | 5 / 10 / 15 mg weekly, 72 weeks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff et al., DOI 10.1056/NEJMoa2206038 |
| SURMOUNT-2 (Lancet 2023) | Adults with obesity/overweight and type 2 diabetes (n=938) | 10 / 15 mg weekly, 72 weeks | −12.8% / −14.7% vs −3.2% placebo | Garvey et al., DOI 10.1016/S0140-6736(23)01200-X |
Common side effects reported in trials
- SURMOUNT-1 (5 / 10 / 15 mg vs placebo): nausea 24.6% / 33.3% / 31.0% vs 9.5%; diarrhoea 18.7% / 21.2% / 23.0% vs 7.3%; constipation 16.8% / 17.1% / 11.7% vs 5.8%; vomiting 8.3% / 10.7% / 12.2% vs 1.7%.
- Most gastrointestinal events were mild to moderate and occurred mainly during dose escalation (Jastreboff et al., 2022).
- The FDA label carries a boxed warning about thyroid C-cell tumours: Zepbound prescribing information (DailyMed).
Individual results differ and results vary. Figures above are group averages from the cited studies, not a prediction for any individual. This summary is for information only and is not medical advice; speak to a licensed healthcare professional.
Frequently asked questions
Which doses of tirzepatide were studied in SURMOUNT-1?
5 mg, 10 mg and 15 mg once weekly for 72 weeks, compared with placebo (Jastreboff et al., NEJM 2022).
What average weight change was seen in SURMOUNT-1?
The mean change in body weight was −15.0%, −19.5% and −20.9% for the 5, 10 and 15 mg doses, vs −3.1% with placebo. Individual results differed.
What were the most common side effects?
Gastrointestinal effects, mainly nausea, diarrhoea, constipation and vomiting, which occurred mostly during dose escalation.
Reviews
There are no reviews yet.